• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经济弱势女性的乳腺癌生存率:延迟诊断和治疗对死亡率的影响。

Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality.

作者信息

Smith Emily Rose, Adams Swann Arp, Das Irene Prabhu, Bottai Matteo, Fulton Jeanette, Hebert James R

机构信息

Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, USA.

出版信息

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2882-90. doi: 10.1158/1055-9965.EPI-08-0221. Epub 2008 Oct 3.

DOI:10.1158/1055-9965.EPI-08-0221
PMID:18835941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2959167/
Abstract

Breast cancer affects thousands each year in the United States, and disproportionately affects certain subgroups. For example, the incidence of breast cancer in South Carolina is lower in African American compared with European American women by approximately 12% to 15%, but their mortality rate is twice as high as in European American women. The purpose of the study was to assess factors associated with breast cancer mortality between African American and European American women. Participants (n=314) in South Carolina's Breast and Cervical Cancer Early Detection Program (SCBCCEDP), which provides breast cancer screening and treatment services, during the years 1996-2004 were included in the study. Data, including tumor characteristics, delay intervals, and race, were examined using the chi(2) test and the Wilcoxon rank-sum test. Cox regression modeling was used to assess the relationship between delay intervals and other factors. No racial differences were found in age at diagnosis, tumor characteristics, or delay intervals. Time delay intervals did not explain differences and mortality rates by race. Survival, however, was affected by prognostic factors as well as by a significant interaction between hormone-receptor status and race. Despite the excellent record of the SCBCCEDP in screening and diagnostic or treatment referrals, the racial disparities in breast cancer mortality continue to exist in South Carolina. These findings highlight the need for future research into the etiology of racial differences, and their impact on breast cancer survival.

摘要

在美国,每年有数千人受到乳腺癌的影响,而且某些亚群体受到的影响尤为严重。例如,南卡罗来纳州非裔美国女性的乳腺癌发病率比欧裔美国女性低约12%至15%,但其死亡率却是欧裔美国女性的两倍。这项研究的目的是评估非裔美国女性和欧裔美国女性中与乳腺癌死亡率相关的因素。参与南卡罗来纳州乳腺癌和宫颈癌早期检测项目(SCBCCEDP)的1996年至2004年间的参与者(n = 314)被纳入该研究,该项目提供乳腺癌筛查和治疗服务。使用卡方检验和Wilcoxon秩和检验对包括肿瘤特征、延迟间隔和种族在内的数据进行了检查。Cox回归模型用于评估延迟间隔与其他因素之间的关系。在诊断年龄、肿瘤特征或延迟间隔方面未发现种族差异。时间延迟间隔并不能解释种族之间的差异和死亡率。然而,生存率受到预后因素以及激素受体状态与种族之间显著相互作用的影响。尽管SCBCCEDP在筛查以及诊断或治疗转诊方面记录出色,但南卡罗来纳州乳腺癌死亡率方面的种族差异仍然存在。这些发现凸显了未来对种族差异的病因及其对乳腺癌生存影响进行研究的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d6/2959167/dc471f1eb2ec/nihms-236638-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d6/2959167/bc4ad06cd9c5/nihms-236638-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d6/2959167/09a563e3b194/nihms-236638-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d6/2959167/dc471f1eb2ec/nihms-236638-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d6/2959167/bc4ad06cd9c5/nihms-236638-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d6/2959167/09a563e3b194/nihms-236638-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d6/2959167/dc471f1eb2ec/nihms-236638-f0003.jpg

相似文献

1
Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality.经济弱势女性的乳腺癌生存率:延迟诊断和治疗对死亡率的影响。
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2882-90. doi: 10.1158/1055-9965.EPI-08-0221. Epub 2008 Oct 3.
2
Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women.社会决定因素对黑人和白人女性乳腺癌死亡率的种族差异的影响。
J Racial Ethn Health Disparities. 2021 Feb;8(1):147-156. doi: 10.1007/s40615-020-00766-y. Epub 2020 May 8.
3
Breast cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.南卡罗来纳州的乳腺癌差异:早期检测、特殊项目及描述性流行病学
J S C Med Assoc. 2006 Aug;102(7):231-9.
4
Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.南卡罗来纳州的前列腺癌差异:早期检测、特殊项目及描述性流行病学
J S C Med Assoc. 2006 Aug;102(7):241-9.
5
Racial disparities in cervical cancer mortality in an African American and European American cohort in South Carolina.南卡罗来纳州非裔美国人和欧裔美国人队列中宫颈癌死亡率的种族差异。
J S C Med Assoc. 2009 Dec;105(7):237-44.
6
Travel distance to screening facilities and completion of abnormal mammographic follow-up among disadvantaged women.贫困女性接受乳腺 X 线筛查的出行距离与异常乳腺 X 线检查结果的后续处理。
Ann Epidemiol. 2017 Jan;27(1):35-41. doi: 10.1016/j.annepidem.2016.08.013. Epub 2016 Aug 31.
7
Disparities in Breast Cancer Incidence, Mortality, and Quality of Care among African American and European American Women in South Carolina.南卡罗来纳州非裔美国女性和欧裔美国女性在乳腺癌发病率、死亡率及医疗质量方面的差异
South Med J. 2016 Jan;109(1):24-30. doi: 10.14423/SMJ.0000000000000396.
8
Regional and racial disparities in breast cancer-specific mortality.乳腺癌特异性死亡率的地区和种族差异。
Soc Sci Med. 2006 Jan;62(2):337-47. doi: 10.1016/j.socscimed.2005.06.038. Epub 2005 Jul 26.
9
Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status.基于组织学分级和激素受体状态定义的乳腺癌亚型发病率的种族差异。
Cancer Causes Control. 2010 Mar;21(3):399-409. doi: 10.1007/s10552-009-9472-2. Epub 2009 Dec 19.
10
Racial disparities in breast cancer mortality in a multiethnic cohort in the Southeast.在东南部的一个多民族队列中,乳腺癌死亡率存在种族差异。
Cancer. 2012 May 15;118(10):2693-9. doi: 10.1002/cncr.26570. Epub 2011 Sep 27.

引用本文的文献

1
Neighborhood Disadvantage, Individual Experiences of Racism, and Breast Cancer Survival.邻里劣势、个人种族主义经历与乳腺癌生存
JAMA Netw Open. 2025 Apr 1;8(4):e253807. doi: 10.1001/jamanetworkopen.2025.3807.
2
An Investigation of Travel Distance and Timeliness of Breast Cancer Treatment Among a Diverse Cohort in the United States.美国不同人群乳腺癌治疗的旅行距离和及时性调查
Int J Environ Res Public Health. 2025 Jan 27;22(2):176. doi: 10.3390/ijerph22020176.
3
The Devastating Impact of the COVID-19 Pandemic on Breast Cancer Care Among Medically Underserved Populations at Two New York City Public Hospitals.

本文引用的文献

1
Is triple negative a prognostic factor in breast cancer?三阴性是乳腺癌的一个预后因素吗?
Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.
2
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.Akt和HER2/neu过表达在非裔美国和拉丁裔乳腺癌女性中的临床意义。
Breast Cancer Res. 2008;10(1):R3. doi: 10.1186/bcr1844. Epub 2008 Jan 10.
3
Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.
新冠疫情对纽约市两家公立医院医疗服务不足人群乳腺癌护理的毁灭性影响。
Ann Surg Open. 2020 Oct 19;1(2):e018. doi: 10.1097/AS9.0000000000000018. eCollection 2020 Dec.
4
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil.安全网健康系统中,休斯顿与巴西南部乳腺癌治疗延迟的比较。
Oncologist. 2022 May 6;27(5):344-351. doi: 10.1093/oncolo/oyac050.
5
Association of Race, Ethnicity, and Socioeconomic Status With Esthesioneuroblastoma Presentation, Treatment, and Survival.种族、族裔和社会经济地位与嗅神经母细胞瘤的表现、治疗及生存的关联
OTO Open. 2022 Feb 9;6(1):2473974X221075210. doi: 10.1177/2473974X221075210. eCollection 2022 Jan-Mar.
6
Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany.新冠疫情对德国普通及专科医疗实践中癌症诊断的影响。
Cancers (Basel). 2021 Jan 22;13(3):408. doi: 10.3390/cancers13030408.
7
Evaluation of Racial, Ethnic, and Socioeconomic Associations With Treatment and Survival in Uveal Melanoma, 2004-2014.2004-2014 年葡萄膜黑色素瘤的治疗和生存与种族、民族和社会经济因素的相关性评估。
JAMA Ophthalmol. 2020 Aug 1;138(8):876-884. doi: 10.1001/jamaophthalmol.2020.2254.
8
Provider delay in treatment initiation and its influence on survival outcomes in women with operable breast cancer.可手术乳腺癌患者治疗开始的延迟及其对生存结局的影响。
Rep Pract Oncol Radiother. 2020 Mar-Apr;25(2):271-275. doi: 10.1016/j.rpor.2020.02.002. Epub 2020 Feb 21.
9
Narrowing Racial Gaps in Breast Cancer: Factors Affecting Probability of Adjuvant Radiation Therapy.缩小乳腺癌的种族差距:影响辅助放疗概率的因素
Adv Radiat Oncol. 2019 Aug 16;5(1):17-26. doi: 10.1016/j.adro.2019.07.014. eCollection 2020 Jan-Feb.
10
Mortality-to-incidence ratios by US Congressional District: Implications for epidemiologic, dissemination and implementation research, and public health policy.按美国国会选区划分的病死率与发病率比:对流行病学、传播和实施研究以及公共卫生政策的启示。
Prev Med. 2019 Dec;129S:105849. doi: 10.1016/j.ypmed.2019.105849. Epub 2019 Nov 1.
新诊断的非裔美国人和白人乳腺癌患者的特征差异:与美国国立癌症研究所的监测、流行病学和最终结果数据库相比的单机构汇编
Cancer. 2007 Aug 15;110(4):876-84. doi: 10.1002/cncr.22836.
4
Breast cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.南卡罗来纳州的乳腺癌差异:早期检测、特殊项目及描述性流行病学
J S C Med Assoc. 2006 Aug;102(7):231-9.
5
Delays in breast cancer diagnosis and treatment by racial/ethnic group.按种族/族裔群体划分的乳腺癌诊断和治疗延误情况。
Arch Intern Med. 2006 Nov 13;166(20):2244-52. doi: 10.1001/archinte.166.20.2244.
6
HER2 therapy: molecular mechanisms of trastuzumab resistance.HER2疗法:曲妥珠单抗耐药的分子机制
Breast Cancer Res. 2006;8(6):215. doi: 10.1186/bcr1612.
7
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.《卡罗来纳乳腺癌研究中的种族、乳腺癌亚型与生存率》
JAMA. 2006 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492.
8
Characteristics of women refusing follow-up for tests or symptoms suggestive of breast cancer.拒绝针对提示乳腺癌的检查或症状进行随访的女性特征。
J Natl Cancer Inst Monogr. 2005(35):33-8. doi: 10.1093/jncimonographs/lgi035.
9
Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment.乳腺癌检测、诊断和治疗起始时间方面的种族不平等。
Med Care. 2005 Feb;43(2):141-8. doi: 10.1097/00005650-200502000-00007.
10
Breast cancer in African-American women.非裔美国女性的乳腺癌
Oncologist. 2005 Jan;10(1):1-14. doi: 10.1634/theoncologist.10-1-1.